This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           March 26, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

Study ties breast gene to high-risk uterine cancer
The Associated Press via ABC News
Women with a faulty breast cancer gene might face a greater chance of rare but deadly uterine tumors despite having their ovaries removed to lower their main cancer risks, doctors are reporting. A study of nearly 300 women with bad BRCA1 genes found four cases of aggressive uterine cancers years after they had preventive surgery to remove their ovaries. That rate is 26 times greater than expected. "One can happen. Two all of a sudden raises eyebrows," and four is highly suspicious, said Dr. Noah Kauff of Memorial Sloan Kettering Cancer Center in New York.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




Annual Meeting attendance nears 1,900
The 45th SGO Annual Meeting on Women’s Cancer drew nearly 1,900 attendees, 43 exhibitors and nine advocacy groups. Save the date for SGO’s 46th annual meeting, March 28-31, 2015, at the Chicago Hilton in Chicago. Thanks to everyone for coming to Tampa and making this year’s meeting a success.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Bariatric surgery tied to drop in uterine cancer risk
MedPage Today
Obese women who maintained weight loss after bariatric surgery seemed to have a 71 percent lower risk of developing uterine cancer as compared with women who were obese and did not undergo surgery. Overall, obesity almost tripled the risk of uterine cancer as compared with non-obese women. The cancer risk posed by obesity declined sharply in the subgroup of women who had bariatric surgery and remained significantly lower in patients who kept the weight off versus those who did not.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


For women's cancers, where you're treated matters
HealthDay News via Philly.com
Where you're treated for ovarian or other gynecologic cancers makes a difference. Women with these conditions live more than a year longer on average if they're treated at hospitals that deal with a large number of these cancers, according to a new study. Researchers looked at data from more than 860,000 patients with ovarian, cervical, uterine, vaginal or vulvar cancer who were treated at nearly 1,700 centers across the United States.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Japanese Mushroom Extract Active Hexose Correlated Compound (AHCC) may have a role in the prevention of HPV-related cancers
Health News Digest
Treating cervical cancer cells with AHCC led to the eradication of HPV, human papillomavirus, as well as a decrease in the rate of tumor growth in-vitro and in-vivo, in research presented. In the study cervical cancer cells were treated with AHCC and incubated for 72 hours with sampling every 24 hours. The study was then repeated in two orthotopic mouse models, one HPV positive and other HPV negative control. The HPV expression was eradicated with once daily AHCC dosing for 90 days with durable response after 30 day observation off treatment. Dr. Smith then repeated the study to confirm findings and added sampling for correlative testing of immune markers to determine the mechanism by which AHCC eradicates the HPV virus.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Mobile app, feedback help cancer survivors lose weight
Akron Beacon Journal Online
When it comes to losing weight, using a mobile app to track progress and getting feedback from a doctor, dietitian or exercise specialist could heavily influence success. A new study by Summa Health System researchers found overweight breast and endometrial cancer survivors lost weight and decreased their waist circumference using the Lose It! smartphone application, paired with support from healthcare providers. At the end of the one-month study, body-mass index (BMI) and waist circumference among participants decreased by 3 to 4 percent.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


High marks for minimal surgery in cervical cancer
MedPage Today
Less-than-radical and minimally invasive surgery for early-stage cervical cancer led to outcomes that compared favorably with results of more extensive procedures, investigators reported here. A study of 51 women showed no recurrences during a median follow-up of 21 months after treatment with simple hysterectomy or cone biopsy plus bilateral pelvic lymph node dissection, Genevieve Bouchard-Fortier, M.D. A comparison trachelectomy open and minimally invasive radical trachelectomy also showed no differences in key outcomes in 100 young women who wanted fertility-preserving surgery, according to researchers.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Veliparib safe, effective among women with BRCA-mutated gynecologic cancers
HemOnc Today
The PARP inhibitor veliparib demonstrated activity with acceptable toxicity among women with recurrent or persistent epithelial, ovarian, peritoneal or fallopian tube cancer who harbored BRCA1 or BRCA2 mutations, according to results of a phase 2 study presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in Tampa, Fla. “One criticism of the PARP drugs is they are not active in patients who have developed resistance to other therapies, but we found veliparib appears to be effective in some platinum-resistant patients with recurrent or persistent disease,” said Dr. Robert L. Coleman.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Cancer doesn't end women's sex lives
MedPage Today
Older female cancer survivors had less interest in sex and less frequent sex, but otherwise had sexual interests and problems similar to those of age-matched women who were cancer free, according to a national survey. Significantly fewer cancer survivors reported having a current sexual partner or having sex within the previous year, but they were similar to the control group in terms of sexual preferences and practices.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Study discovers genetic cause of rare type of ovarian cancer
Medical Xpress
The cause of a rare type of ovarian cancer that most often strikes girls and young women has been uncovered by an international research team led by the Translational Genomics Research Institute (TGen), according to a study published online by the renowned scientific journal, Nature Genetics. The findings revealed a "genetic superhighway" mutation in a gene found in the overwhelming majority of patients with small cell carcinoma of the ovary, hypercalcemic type, also known as SCCOHT.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


OVARIAN CANCER


Bevacizumab may improve progression free survival in platinum-resistant ovarian cancer
2 minute medicine
A study in the March 20 Journal of Clinical Oncology found that combining bevacizumab with standard chemotherapy improved progression free survival and objective response rate in platinum-resistant ovarian cancer. Adding bevacizumab did not significantly affect overall survival
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

March 19, 2014
March 12, 2014
March 5, 2014
Feb, 26, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063